(S)-2-([1,1’-biphenyl]-4-yl)-2-((tert-butoxycarbonyl)amino)acetic acid | 225517-19-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (S)-2-([1,1’-biphenyl]-4-yl)-2-((tert-butoxycarbonyl)amino)acetic acid
• 英文别名: N-tert-butoxycarbonyl-(S)-(4-biphenyl)glycine；(S)-Biphenyl-4-YL-tert-butoxycarbonylamino-acetic acid；(2S)-2-[(2-methylpropan-2-yl)oxycarbonylamino]-2-(4-phenylphenyl)acetic acid
• CAS: 225517-19-1
• 化学式: C₁₉H₂₁NO₄
• 分子量: 327.38
• InChiKey: IGQRMCQSKDTFDV-INIZCTEOSA-N

物化性质

• 沸点：
  512.4±50.0 °C(Predicted)
• 密度：
  1.178±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  24
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.26
• 拓扑面积：
  75.6
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (S)-2-([1,1’-biphenyl]-4-yl)-2-((tert-butoxycarbonyl)amino)acetic acid 在 盐酸 、 silver benzoate 、 三乙胺 作用下， 以 乙醚 、 乙酸乙酯 为溶剂， 反应 3.0h， 生成 3-amino-3-(4-biphenyl)propionic acid methyl ester
  参考文献：
  名称：

  Substituted 3-amino biaryl propionic acids as potent VLA-4 antagonists

  摘要：

  A series of substituted N-(3,5-dichlorobenzenesulfonyl)-(L)-prolyl- and (L)-azetidyl-beta-biaryl beta-alanine derivatives was prepared as selective and potent VLA-4 antagonists. The 2,6-dioxygenated biaryl substitution pattern is important for optimizing potency. Oral bioavailability was variable and may be a result of binding to circulating plasma proteins. (C) 2002 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(02)00460-2
• 作为产物：
  描述：

  B-苯基-硼酸二甲酯 在 盐酸 、 lithium hydroxide 、 四(三苯基膦)钯 、 potassium carbonate 作用下， 以 乙醇 、 甲苯 为溶剂， 反应 3.0h， 生成 (S)-2-([1,1’-biphenyl]-4-yl)-2-((tert-butoxycarbonyl)amino)acetic acid
  参考文献：
  名称：

  Substituted 3-amino biaryl propionic acids as potent VLA-4 antagonists

  摘要：

  A series of substituted N-(3,5-dichlorobenzenesulfonyl)-(L)-prolyl- and (L)-azetidyl-beta-biaryl beta-alanine derivatives was prepared as selective and potent VLA-4 antagonists. The 2,6-dioxygenated biaryl substitution pattern is important for optimizing potency. Oral bioavailability was variable and may be a result of binding to circulating plasma proteins. (C) 2002 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(02)00460-2

文献信息

• Substituted ureas as cell adhesion inhibitors
  申请人：Merck & Co., Inc.

  公开号：US06353099B1

  公开（公告）日：2002-03-05

  Compounds of Formula I are antagonists of VLA-4 and/or &agr;4&bgr;7, and as such are useful in the inhibition or prevention of cell adhesion and cell-adhesion mediated pathologies. These compounds may be formulated into pharmaceutical compositions and are suitable for use in the treatment of AIDS-related dementia, allergic conjunctivitis, allergic rhinitis, Alzheimer's disease, asthma, atherosclerosis, autologous bone marrow transplantation, certain types of toxic and immune-based nephritis, contact dermal hypersensitivity, inflammatory bowel disease including ulcerative colitis and Crohn's disease, inflammatory lung diseases, inflammatory sequelae of viral infections, meningitis, multiple sclerosis, multiple myeloma, myocarditis, organ transplantation, psoriasis, pulmonary fibrosis, restenosis, retinitis, rheumatoid arthritis, septic arthritis, stroke, tumor metastasis, uveititis, and type I diabetes.

  公式I的化合物是VLA-4和/或α4β7的拮抗剂，因此在抑制或预防细胞粘附和细胞粘附介导的病理过程中非常有用。这些化合物可以制成药物组合物，并适用于治疗艾滋病相关痴呆、过敏性结膜炎、过敏性鼻炎、阿尔茨海默病、哮喘、动脉粥样硬化、自体骨髓移植、某些类型的毒性和免疫性肾炎、接触性皮肤过敏、炎症性肠病包括溃疡性结肠炎和克罗恩病、炎症性肺部疾病、病毒感染的炎症后遗症、脑膜炎、多发性硬化症、多发性骨髓瘤、心肌炎、器官移植、牛皮癣、肺纤维化、再狭窄、视网膜炎、类风湿性关节炎、败血性关节炎、中风、肿瘤转移、葡萄膜炎和I型糖尿病的治疗。
• Alzheimer’s Disease: Identification and Development of β-Secretase (BACE-1) Binding Fragments and Inhibitors by Dynamic Ligation Screening (DLS)
  作者：María Isabel Fernández-Bachiller、André Horatscheck、Michael Lisurek、Jörg Rademann

  DOI：10.1002/cmdc.201300078

  日期：2013.7

  Irreversibly formed fragment combination products of 1 with the initial peptide sequence were active and confirmed the targeting of the active site through the ethane‐1,2‐diamine isostere. Finally, structure‐assisted combination of fragment 1 with secondary fragments that target the S1 site in hit optimization yielded novel, entirely fragment‐based BACE‐1 inhibitors with up to 30‐fold improved binding affinity

  据报道，动态连接筛选（DLS）是一种基于片段的药物发现（FBDD）方法，适用于天冬氨酸蛋白酶β-分泌酶（BACE-1）。为此，设计并合成了三种新的荧光共振能量转移（FRET）衬底。它们的动力学参数（V max，K M和k cat确定）并与市售底物进行比较。其次，基于瑞典突变底物序列，将肽醛设计为化学反应抑制剂（CRI）。此CRI与蛋白酶，FRET底物，和一种胺每孔由胺文库，将其组装由最大公共子（MCS）的方法所采取的温育后，揭示该片段3-（3-氨基苯基）-2- ħ - chromen-2-one（1）是竞争性BACE-1抑制剂，可增强CRI的活性。具有初始肽​​序列的不可逆形成的片段结合产物1具有活性，并证实了通过1,2,2-二胺等位基因靶向活性位点。最后，片段1的结构辅助组合通过在命中优化中靶向S1位点的二级片段，产生了全新的，完全基于片段的BACE-1抑制剂，结合亲和力提高了30倍。通
• <i>N</i>‐Boc‐Protected α‐Amino Acids by 1,3‐Migratory Nitrene C(sp³)−H Insertion
  作者：Bing Zhou、Chen‐Xi Ye、Eric Meggers

  DOI：10.1002/ejoc.202300296

  日期：2023.7.8

  N‐Boc‐protected α‐amino acids are synthesized in two steps from linear or branched carboxylic acid feedstocks. In the first step, the carboxylic acid is coupled with tert‐butyl aminocarbonate (BocNHOH) to generate azanyl ester (acyloxycarbamate) RCO₂NHBoc. In the second step, this azanyl ester undergoes a stereocontrolled iron‐catalyzed 1,3‐nitrogen migration to generate the N‐Boc‐protected non‐racemic α‐amino acid. This straightforward protocol is applicable to the catalytic asymmetric synthesis of α‐monosubstituted α‐amino acids with aryl, alkenyl, and alkyl side chains. Furthermore, α,α‐disubstituted α‐amino acids are accessible in an enantioconvergent fashion from racemic carboxylic acids. The new method is also advantageous for the synthesis of α‐deuterated α‐amino acids. N‐Boc‐protected α‐amino acids synthesized using this two‐step protocol are ready‐to‐use building blocks.

  摘要N-叔丁氧羰基保护的α-氨基酸由线性或支链羧酸原料分两步合成。第一步，羧酸与氨基甲酸叔丁酯（BocNHOH）偶联生成偶氮酯（酰氧基氨基甲酸酯）RCO2NHBoc。在第二步中，该氮杂环戊烯酯经过立体控制的铁催化 1,3 氮迁移，生成 N-Boc 保护的非亲和 α-氨基酸。这种直接的方案适用于催化不对称合成带有芳基、烯基和烷基侧链的 α-单取代 α-氨基酸。此外，α,α-二取代的α-氨基酸可以从外消旋羧酸中以对映转化的方式获得。这种新方法还有利于合成α-氚代α-氨基酸。采用这种两步法合成的 N-Boc 保护的 α- 氨基酸是即用型构筑模块。
• Enantioselective synthesis of phenylglycines using (−) sparteine•s-BuLi complex
  作者：Normand Voyer、Johanne Roby、Sylvain Chénard、Claude Barberis

  DOI：10.1016/s0040-4039(97)01515-3

  日期：1997.9

  The enantioselective synthesis of N-t-Boc protected phenylglycine derivatives is reported. The synthetic strategy involved the enantioselective deprotonation of N-t-Boc-N-TMS protected benzylamines using the (-) sparteine.s-BuLi complex. (C) 1997 Published by Elsevier Science Ltd.